Empire Financial Management Company LLC Makes New $222,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Empire Financial Management Company LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,000 shares of the medical research company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $3,173,000. World Investment Advisors LLC boosted its stake in Edwards Lifesciences by 1,660.7% during the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company’s stock valued at $4,770,000 after acquiring an additional 68,172 shares during the last quarter. Wilmington Savings Fund Society FSB grew its holdings in Edwards Lifesciences by 147.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company’s stock worth $601,000 after acquiring an additional 5,420 shares in the last quarter. Destination Wealth Management raised its stake in shares of Edwards Lifesciences by 2.8% in the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company’s stock valued at $463,000 after purchasing an additional 193 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Edwards Lifesciences by 0.7% in the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company’s stock worth $2,609,000 after purchasing an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,853 shares of company stock valued at $5,163,062 over the last three months. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on EW. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI dropped their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.25.

Edwards Lifesciences Trading Up 6.7 %

Shares of EW stock opened at $75.15 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a 50-day simple moving average of $70.93 and a 200 day simple moving average of $71.02. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The stock has a market capitalization of $44.18 billion, a P/E ratio of 10.78, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same period in the previous year, the firm earned $0.66 EPS. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.